EWGs Posters exhibited during the Conference
Steering Committee
Anthelmintics EWG
Bioequivalence EWG
Biologicals EWG
Biologicals EWG Subgroups
Medicated Premixes EWG
MRK EWG
Pharmaceutical Combination Products EWG
Pharmacovigilance EWG
Quality EWG
Quality EWG Subgroups
Safety EWG
Why WOAH is a strong advocate of VICH? – M. Szabo
How is VICH responding to global needs in a new era? – M. Lucia
VICH achievements – H. Marion
Restructuring (and future vision) – S. Iwamoto
VICH workplan – M. Churchill
The view of a VICH Forum member – Y. Kosenko
How VICH guidelines are developed, implemented and used – B. Boenisch
How VICH guidelines implement the 3Rs in safety studies – E. Werner
Challenges and perspectives in adopting VICH guidelines in VICH Forum countries/regions and how to overcome them – A. Ogutu
Scientific topic 1: Safety of monoclonal antibodies – C. Stirling
Scientific topic 2: Pharmacovigilance and signal management – K. Schirmann
Scientific topic 3:– bioequivalence and dissolution testing – M. Martinez
GL topic 1: anthelmintics – A. Phillippi-Taylor
GL topic 2: Good manufacturing practice for active pharmaceutical ingredients – M. Huynh
GL topic 3: pharmaceutical development – M. Huynh
International collaborations – M. Bassi
GMP Inspections Reliance Programmes and Mutual Recognition Agreements – G. Verdier & P. Krauze
Regional collaboration and mutual reliance – I. Ravengai
New science in veterinary biologics – K. Sato
New science and reduction in the use of experimental animals – S. Adler-Flindt
Real world evidence and big data – R. Carapeto
The expectations from a VICH Forum member – B. Borges Cordeiro
Inspired by VICH: International Forum on in vitro diagnostics – J. Essolomwa
Supported by VICH: Regulatory convergence – C. du Marchie Sarvaas
The Vision for the future – I. Claassen